PO.TB07.03 · 肿瘤生物学

Ontario Tumour Bank:以高质量样本和数据加速商业化肿瘤学研发

Ontario Tumour Bank: Accelerating commercial oncology research and development with quality samples and data

海报缩略图:Ontario Tumour Bank:以高质量样本和数据加速商业化肿瘤学研发
编号 4812 展板 4 时间 4/21 09:00–12:00 区域 Section 26 主讲 Riley Cox, BS;MS
分会场 Contextual Determinants of Cancer Stemness and Tumor Aggressiveness
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Riley Cox1, Katarina Maksimovic1, Larry Phouthavongsy1, Anumta Amir1, Ilinca Lungu1, Terry Hawrysh2, Dianne Chadwick1, Lincoln Stein1

1Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, ON, Canada,2Patient and Family Advisory Council, Ontario Institute for Cancer Research, Toronto, ON, Canada

摘要 Abstract

中文摘要
Ontario Tumour Bank(OTB,安大略肿瘤库)是安大略癌症研究所(Ontario Institute for Cancer Research)的核心研究资源,该研究所是一家协作型研究机构,致力于开展并推动研究,以便更早地发现癌症并更有效地治疗癌症。凭借在生物样本库领域20余年的专业经验,OTB已从30余个实体瘤部位、22,500余名参与者中收集了150,000余份样本和15,000余幅全切片图像(WSIs)。每一例肿瘤病例均配有全面的注释,涵盖长达5年的诊断、治疗和健康数据。OTB在支持研究方面业绩卓著,已被200余篇出版物致谢,并获70,000余次引用。近期,OTB来自商业研究客户的需求日益增长。OTB的样本和数据可用于多种商业用途,包括用于快速药物筛选的新鲜肿瘤组织;用于代谢组学的冷冻肿瘤组织及癌旁正常组织;用于诊断检测开发的福尔马林固定石蜡包埋(FFPE)肿瘤组织;用于癌症检测与监测的预测性血液检测的血浆;以及与纵向健康记录数据相结合、用于预后AI模型开发的WSIs。像OTB这样的学术型生物样本库在与商业研究客户合作时面临若干挑战,包括确保其资源对商业研究界可见且可获取,以及获得适当的参与者知情同意、伦理和合同批准。OTB通过多种方式缓解了这些挑战:请参与者同意一份宽泛的知情同意书,其中包含在商业研究中使用其样本和数据;并建立了一个面向研究者的网站(ontariotumourbank.ca),使客户能够在线提交咨询并启动样本和数据申请流程。每份申请由OTB专职的资深客户协调员接收,该协调员是每位客户的中心联络人,并从始至终推进每个项目。为满足不断变化的研究需求,商业客户可获得OTB深厚的"研究就绪"库存,以及定制的新鲜肿瘤和血液采集样本——这些样本在采集后立即隔夜运送。过去5年间,向商业客户(包括加拿大、美国及全球由风险投资支持的生物技术初创企业)提供的项目、样本和数据的数量与比例稳步增长,现已占OTB业务的三分之一。通过简化商业客户的申请流程,OTB展现了其满足该领域未被满足需求的能力,包括研究与医学中新兴的预测性AI模型开发。支持商业研究项目确保了对OTB深厚的高质量样本和数据库存的获取,符合我们慷慨的患者参与者支持多样化学术与产业研究的意愿,同时也为OTB的长期财务可持续性作出贡献。
查看英文原文 English abstract
The Ontario Tumour Bank (OTB) is a core research resource at the Ontario Institute for Cancer Research, a collaborative research institute that conducts and enables research to find cancer earlier and treat it more effectively. With 20+ years of expertise in biobanking, OTB has collected 150,000+ samples and 15,000+ whole slide images (WSIs) from 22,500+ participants across 30+ solid tumor sites. Each oncology case is comprehensively annotated with diagnostic, treatment and health data for up to 5 years. OTB has a strong record of supporting research, with acknowledgements in 200+ publications and 70,000+ citations. Recently, OTB has experienced an increased demand from commercial research clients. OTB's samples and data can be used for many commercial applications, including fresh tumor tissue for rapid drug screening; frozen tumor and normal adjacent tissue for metabolomics; formalin-fixed paraffin-embedded tumor tissue for diagnostic assay development; plasma for predictive blood tests for cancer detection and monitoring; and WSIs combined with longitudinal health record data for prognostic AI model development. Academic biobanks such as OTB have several challenges when working with commercial research clients. These include ensuring its resources are visible and accessible to the commercial research community, as well as obtaining appropriate participant consent, ethics and contractual approvals. OTB has mitigated these challenges by asking participants to agree to a broad informed consent that includes use of their samples and data in commercial research and creating a researcher-focused website ( ontariotumourbank.ca ) that allows clients to submit inquiries and start the sample and data request process online. Each request is received by OTB's dedicated senior client coordinator, who is the central point-of-contact for each client and facilitates each project from start to finish. To meet evolving research needs, commercial clients are provided access is to OTB's deep “research ready” inventory as well as custom fresh tumor and blood collections shipped overnight immediately after collection. The number and proportion of projects, samples and data provided to commercial clients - including venture capital-supported biotechnology startups in Canada, the US and globally - has steadily increased over the past 5 years and now represents 1/3 of OTB's business. By streamlining the request process for commercial clients, OTB has demonstrated its ability to meet the unmet demands of this sector, including emerging predictive AI model development in research and medicine. Supporting commercial research projects ensures that access to OTB's deep inventory of quality samples and data is consistent with the wishes of our generous patient participants to support diverse academic and industry research, all while contributing to OTB's long-term financial sustainability.
利益披露 Disclosure
R. Cox, None.. K. Maksimovic, None.. L. Phouthavongsy, None.. A. Amir, None.. I. Lungu, None.. T. Hawrysh, None.. D. Chadwick, None.. L. Stein, None.

← 返回 AACR 2026 检索